This article looks at what a transition to propellants with lower Global Warming Potential will involve and the lessons that can be learned from the industry’s earlier transition from CFCs to HFAs. Key issues that need to be addressed as formulators learn to work with propellants such as HFA 152a and HFO 1234ze include solubility of the active, the profile of the emitted spray, droplet size and evaporation, and electrostatic characteristics.
Aptar Pharma offers a comprehensive suite of services for those looking to accelerate their transition to low carbon MDIs including the Nanopharm SmartTrack™ platform which provides a wealth of information for formulation optimization.
Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery
This Might Also Be of Interest
Using digital healthcare to improve patient compliance and adherence
Webinars, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Brand Differentiation, Product Solutions
Towards a More Sustainable Future with Metered Dose Inhalers
Webinars, Pharmaceutical, Sustainability, Drug Delivery Innovations, Brand Differentiation, Market Insights, Product Solutions
Aptar Pharma talks targeted drug delivery to the upper airways
Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Drug Delivery Innovations, Brand Differentiation
Moving Toward a More Sustainable Future With pMDIs
Publications, Pharmaceutical, Product Solutions, Sustainability, Innovation & Insights, Drug Delivery Innovations, Brand Differentiation
